{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:47:45Z","timestamp":1791830865695,"version":"4.3.4"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204443","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T14:05:27Z","timestamp":1538661927000},"page":"e0204443","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-5401","authenticated-orcid":true,"given":"Fabrizio","family":"Schifano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-1540","authenticated-orcid":true,"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"issue":"2","key":"ref1","first-page":"80","article-title":"Self-Medication, Health and Online Orders: An Online Survey","volume":"79","author":"C. Eichenberg","year":"2017"},{"issue":"3","key":"ref2","first-page":"270","article-title":""Pharming": the abuse of prescription and over-the-counter drugs in teens","volume":"19","author":"D.A. Levine","year":"2007"},{"issue":"2","key":"ref3","first-page":"82","article-title":"Over the counter medicine abuse- a review of the literature","volume":"18","author":"R.J. Cooper","year":"2013"},{"issue":"7","key":"ref4","first-page":"1474","article-title":"The birth of the e-clinic. Continuity or transformation in the UK governance of pharmaceutical consumption?","volume":"61","author":"N. Fox","year":"2005"},{"issue":"4","key":"ref5","first-page":"287","article-title":"Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources","volume":"9","author":"L. Manchikanti","year":"2006"},{"key":"ref6","unstructured":"National Association of Boards of Pharmacy (NABP). Internet drug outlet identification program. July 2012. Available from: https:\/\/safemedsonline.org\/wp-content\/uploads\/2012\/06\/NABP-Internet-Drug-Outlet-Report_final_13Jul2012-1.pdf<\/ext-link> (2012). Cited November, 11th 2017."},{"key":"ref7","unstructured":"European Medicines Agency (EMA). Buying medicine online. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000630.jsp&mid=WC0b01ac05808fd210<\/ext-link> (2015). Cited November 11th, 2017."},{"key":"ref8","unstructured":"Council of Europe, European directorate for the quality of medicines and healthcare, Agency for medicinal products and medical devices of Croatia. OTC medicines: the role of good classification practices in promoting medication safety and accessibility in Europe. November 2014. Available from: https:\/\/www.edqm.eu\/sites\/default\/files\/report_pho_expert_final_05_2015.pdf<\/ext-link> (2015). Cited November 11th, 2017."},{"issue":"4","key":"ref9","first-page":"793","article-title":"Changes in over-the-counter drug misuse over 20 years: perceptions from Scottish pharmacists","volume":"38","author":"J. Wright","year":"2016"},{"issue":"7","key":"ref10","first-page":"451","article-title":"Drug Misuse in Adolescents Presenting to the Emergency Department. Toxicology Investigators Consortium (ToxIC)","volume":"33","author":"Y. Finkelstein","year":"2017"},{"issue":"3","key":"ref11","first-page":"151","article-title":"Abuse of medications that theoretically are without abuse potential","volume":"108","author":"R.R. Reeves","year":"2015"},{"key":"ref12","first-page":"1","article-title":"Nonmedical use of over-the-counter medications is significantly associated with nonmedical use of prescription drugs among university students","volume":"16","author":"V.T. Le","year":"2016"},{"key":"ref13","first-page":"241","article-title":"\u201cI just wanted to tell you that loperamide WILL WORK\u201d: a web-based study of extra-medical use of loperamide","volume":"130","author":"R. Daniulaityte","year":"2013"},{"key":"ref14","unstructured":"Grey Pages: The Merits of High Dose Loperamide for Opiate Withdrawal. Available from: http:\/\/derekwmeyer.blogspot.com\/2012\/03\/merits-of-highdose-loperamide-for.html<\/ext-link> (2012). Cited November 11th, 2017."},{"key":"ref15","unstructured":"Finch, M. How to Use Loperamide for Opiate Withdrawal (2015). Available from: http:\/\/opiateaddictionsupport.com\/how-to-use-loperamidefor-opiate-withdrawal\/<\/ext-link> (2015). Cited November 2nd, 2017."},{"key":"ref16"},{"key":"ref17","unstructured":"Drugs-forum. Loperamide. Available from: https:\/\/drugs-forum.com\/threads\/drug-addicts-only-loperamide-imodium.40776\/<\/ext-link> Cited November 27th, 2017."},{"key":"ref18","unstructured":"Erowid. My New Favorite OTC High. Loperamide for methylphenidate comedown. 2014. Available from: https:\/\/erowid.org\/experiences\/exp.php?ID=103598<\/ext-link> (2014). Cited November 11th, 2017."},{"key":"ref19","unstructured":"New York Times. MAY 10, 2016. Addicts Who Can\u2019t Find Painkillers Turn to Anti-Diarrhea Drugs. Available from: https:\/\/www.nytimes.com\/2016\/05\/11\/health\/imodium-opioid-addiction.html?_r=0<\/ext-link> (2016). Cited November 11th, 2017."},{"key":"ref20","unstructured":"Erowid. Absolutely awesome loperamide. 2007. Available from: https:\/\/www.erowid.org\/experiences\/exp.php?ID=66159<\/ext-link> (2007). Cited November 11th, 2017."},{"key":"ref21","unstructured":"Erowid. Loperamide. 2016. Available from: https:\/\/erowid.org\/pharms\/loperamide\/<\/ext-link> (2016). Cited November 12th, 2017."},{"issue":"2S","key":"ref22","first-page":"S45","article-title":"Loperamide misuse and abuse","volume":"57","author":"H. Miller","year":"2003"},{"key":"ref23","first-page":"1276","article-title":"Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse\u2014New York, 2008\u20132016","volume":"2016","author":"W. Eggleston"},{"issue":"1","key":"ref24","first-page":"83","article-title":"Loperamide Abuse Associated With Cardiac Dysrhythmia and Death","volume":"69","author":"W. Eggleston","year":"2017"},{"key":"ref25","first-page":"677","article-title":"Loperamide-Related Deaths in North Carolina","volume":"40","author":"S.C. Bishop-Freeman","year":"2016"},{"issue":"1","key":"ref26","first-page":"73","article-title":"Epidemiologic Trends in Loperamide Abuse and Misuse","volume":"69","author":"J.P. Vakkalanka","year":"2017"},{"issue":"2","key":"ref27","first-page":"249","article-title":"Loperamide Trends in Abuse and Misuse Over 13 Years: 2002\u20132015","volume":"37","author":"D.R. Lasoff","year":"2017"},{"issue":"1","key":"ref28","first-page":"73","article-title":"Misuse and Abuse of Loperamide: A New Look at a Drug with "Low Abuse Potential"","volume":"53","author":"S.W. Borron","year":"2017"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209705","article-title":"Loperamide dependence and abuse","author":"R. MacDonald","year":"2015"},{"key":"ref30","unstructured":"Food and Drug Administration (FDA). Imodium Label, 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/017694s052lbl.pdf<\/ext-link> (2016). Cited November 30th, 2017."},{"issue":"6","key":"ref31","first-page":"812","article-title":"Abuse potential of loperamide","volume":"28","author":"J.H. Jaffe","year":"1980"},{"issue":"1","key":"ref32","first-page":"18","article-title":"Loperamide, the "Poor Man's Methadone": Brief Review","volume":"49","author":"C.N. Stanciu","year":"2017"},{"key":"ref33","first-page":"454","article-title":"Not your regular high: cardiac dysrhythmias caused by loperamide","volume":"54","author":"R.S. Wightman","year":"2016"},{"key":"ref34","first-page":"1083","article-title":"The long QT teaser: loperamide abuse","volume":"128","author":"E.O. Enakpene","year":"2015"},{"key":"ref35","first-page":"952","article-title":"Cardiac conduction disturbance after loperamide abuse","volume":"52","author":"J.M. Marraffa","year":"2014"},{"key":"ref36","unstructured":"Food and Drug Administration (FDA). Drug Safety Communications. FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Safety Announcement [6-7-2016] Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm504617.htm<\/ext-link> (2016). Cited November 2nd, 2017."},{"key":"ref37","unstructured":"Heads of Medicines Agency (HMA) and European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module VI: collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). 2017. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2017\/08\/WC500232767.pdf<\/ext-link> (2017). Cited November 14th, 2017."},{"key":"ref38","unstructured":"MedDRA, Medical Dictionary for Adverse Drug Reactions. Introductory Guide Version 20.1, 2017: Available from: https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_20_1_english_0.pdf<\/ext-link> (2017). Cited November 14th, 2017."},{"key":"ref39","unstructured":"MedDRA, Medical Dictionary for Adverse Drug Reactions. Introductory Guide for Standardised MedDRA Queries Version 20.1, 2017. Available from: https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_20_1_english.pdf<\/ext-link> (2017). Cited November 14th, 2017."},{"key":"ref40","unstructured":"EudraVigilance. European database of suspected adverse drug reaction reports. Available from: http:\/\/www.adrreports.eu<\/ext-link> Cited 22ndJune, 2018."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fphar.2018.00239","article-title":"Is There A Potential Of Misuse For Venlafaxine And Bupropion? Analysis of The European Medicines\u2019 Agency\/EMA Adverse Drug Reactions Database","volume":"9","author":"F. Schifano","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref42","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme. Loperamide interactive drug analysis profile. Available from: https:\/\/info.mhra.gov.uk\/drug-analysis-profiles\/dap.html?drug=.\/UK_EXTERNAL\/NONCOMBINED\/UK_NON_000127539853.zip&agency=MHRA<\/ext-link> (2018). Cited 22nd,June 2018."},{"key":"ref43","unstructured":"Food and Drug Administration Adverse Event Reporting System (FAERS) Public Dashboard. Available from: https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis<\/ext-link> (2018). Cited 22nd June, 2018."},{"issue":"8","key":"ref44","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.biopha.2013.04.012","article-title":"Inhibition of P-glycoprotein and glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7\/ADM cells","volume":"67","author":"Y. Zhang","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"ref45","first-page":"27","article-title":"P-glycoprotein Inhibition for Optimal Drug Delivery","volume":"7","author":"M.L. Amin","year":"2013"},{"issue":"2","key":"ref46","first-page":"e12505","article-title":"Loperamide cardiotoxicity: \u201cA Brief Review\u201d","volume":"23","author":"T. Akel","year":"2018"},{"key":"ref47","unstructured":"Erowid. Recipe for withdrawals, 2012. Available from: https:\/\/erowid.org\/experiences\/exp.php?ID=98136<\/ext-link> (2012). Cited November 11th, 2017."},{"key":"ref48","unstructured":"Erowid. Wouldn't Say That This Is Anything Amazing. Loperamide & Black Pepper, 2010. Available from: https:\/\/erowid.org\/experiences\/exp.php?ID=91308<\/ext-link> (2010). Cited November 11th, 2017."},{"issue":"Suppl 3","key":"ref49","first-page":"S11","article-title":"Loperamide: a pharmacological review","volume":"7","author":"D.E. Baker","year":"2007"},{"key":"ref50","first-page":"57","article-title":"Herbal modulation of P-glycoprotein","volume":"36","author":"S. Zhou","year":"2004"},{"key":"ref51","first-page":"1","article-title":"Trends in dextromethorphan cough and cold products: 2000\u20132015 National Poison Data System intentional abuse exposure calls","volume":"20","author":"S. Karami","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"issue":"8","key":"ref52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.healthpol.2016.06.008","article-title":"Misuse of OTC drugs in Poland","volume":"120","author":"T. Zaprutko","year":"2016","journal-title":"Health Policy"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/7854_2015_422","article-title":"Over-the-Counter Codeine-from Therapeutic Use to Dependence, and the Grey Areas in Between","volume":"34","author":"S. Nielsen","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"issue":"2016","key":"ref54","first-page":"34","article-title":"High doses of loperamide can cause serious cardiac events","author":"B.J Rose","journal-title":"PharmacyToday"},{"key":"ref55","first-page":"1","article-title":"Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders","volume":"159","author":"L. Nguyen","year":"2016"},{"issue":"7","key":"ref56","first-page":"659","article-title":"Loperamide metabolite-induced cardiomyopathy and QTc prolongation","volume":"55","author":"Z. Bhatti","year":"2017"},{"issue":"2","key":"ref57","first-page":"245","article-title":"Clinical Review: Loperamide Toxicity","volume":"70","author":"P.E. Wu","year":"2017"},{"key":"ref58","first-page":"747","article-title":"Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons","volume":"45","author":"J. Church","year":"1994"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5040176","article-title":"Loperamide induced life threatening ventricular arrhythmia","author":"A. Upadhyay","year":"2016"},{"key":"ref60","first-page":"1133","article-title":"Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic","volume":"389","author":"J. Kang","year":"2016"},{"key":"ref61","first-page":"225","article-title":"Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist- loperamide","volume":"90","author":"N. Nozaki-Taguchi","year":"1999"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4061980","article-title":"Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature","author":"O. Mukarram","year":"2016"},{"issue":"2S","key":"ref63","first-page":"S63","article-title":"Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse","volume":"57","author":"K.A. Swank","year":"2003"},{"key":"ref64","article-title":"Cardiac Dysrhythmias Associated With Substitutive Use of Loperamide: A Systematic Review","author":"I.B. Riaz","year":"2017"},{"issue":"10","key":"ref65","first-page":"1230","article-title":"Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse","volume":"27","author":"P. Vaughn","year":"2016"},{"issue":"4","key":"ref66","first-page":"33","article-title":"Unexpected Serious Cardiac Arrhythmias in the Setting of Loperamide Abuse","volume":"100","author":"S. Rasla","year":"2013"},{"issue":"3","key":"ref67","first-page":"355","article-title":"Torsades de pointes with high-dose loperamide","volume":"50","author":"P.M. Kozak","year":"2017"},{"issue":"5","key":"ref68","first-page":"495","article-title":"Loperamide toxicokinetics: Serum concentrations in the overdose setting","volume":"53","author":"W. Eggleston","year":"2015"},{"issue":"5","key":"ref69","first-page":"402","article-title":"Methadone Management of Withdrawal Associated With Loperamide-related Opioid Use Disorder","volume":"11","author":"R.J. Leo","year":"2017"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:35:37Z","timestamp":1540280137000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204443"}},"subtitle":[],"editor":[{"given":"Y-h.","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204443","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]}}}